Search results

141 results

Sorted by Relevance . Sort by Date

Guidance Remove Guidance filter
Proposed Remove Proposed filter
Technology appraisal guidance Remove Technology appraisal guidance filter
COVID-19 rapid guidelines Remove COVID-19 rapid guidelines filter
Diagnostics guidance Remove Diagnostics guidance filter

Ibrutinib with corticosteroids for untreated chronic graft versus host disease [ID3792]

Proposed [GID-TA10722] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Secukinumab for treating enthesitis-related arthritis or juvenile psoriatic arthritis [ID3738]

Proposed [GID-TA10598] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Treosulfan with fludarabine for non-malignant disease before allogeneic stem cell transplant [ID1540]

Proposed [GID-TA10453] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Dulaglutide for treating type 2 diabetes [ID1451]

Proposed [GID-TA10439] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Gosuranemab for treating progressive supranuclear palsy [ID1607]

Proposed [GID-TA10553] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Autologous haematopoietic stem cell transplantation for treating multiple sclerosis (ID1111)

Proposed [GID-TA10306] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Palbociclib for treating high-risk early breast cancer after neoadjuvant chemotherapy [ID3846]

Proposed [GID-TA10723] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Daratumumab in combination for untreated multiple myeloma when high-dose chemotherapy with stem cell transplant is unsuitable [ID3843]

Proposed [GID-TA10726] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Netarsudil for treating open angle glaucoma or ocular hypertension [ID1078]

Proposed [GID-TA10431] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Cabotegravir with rilpivirine for the oral treatment of HIV-1 [ID3731]

Proposed [GID-TA10604] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Remdesivir for treating COVID-19 [ID3808]

Proposed [GID-TA10721] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Pembrolizumab with docetaxel for treating hormone-relapsed metastatic prostate cancer untreated with chemotherapy [ID3801]

Proposed [GID-TA10668] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Eryaspase with chemotherapy for previously treated advanced or metastatic pancreatic cancer [ID3781]

Proposed [GID-TA10637] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Naxitamab with GM-CSF for treating relapsed or refractory high-risk neuroblastoma [ID3769]

Proposed [GID-TA10638] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed
Eflornithine with sulindac for treating familial adenomatous polyposis [ID1543]

Proposed [GID-TA10536] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Proposed

Filter (5 in use)

Type 1 selected

Status 1 selected

Last updated

Guidance programme 3 selected

141 results

Ibrutinib with corticosteroids for untreated chronic graft versus host disease [ID3792]

Secukinumab for treating enthesitis-related arthritis or juvenile psoriatic arthritis [ID3738]

Treosulfan with fludarabine for non-malignant disease before allogeneic stem cell transplant [ID1540]

Dulaglutide for treating type 2 diabetes [ID1451]

Gosuranemab for treating progressive supranuclear palsy [ID1607]

Autologous haematopoietic stem cell transplantation for treating multiple sclerosis (ID1111)

Palbociclib for treating high-risk early breast cancer after neoadjuvant chemotherapy [ID3846]

Daratumumab in combination for untreated multiple myeloma when high-dose chemotherapy with stem cell transplant is unsuitable [ID3843]

Netarsudil for treating open angle glaucoma or ocular hypertension [ID1078]

Cabotegravir with rilpivirine for the oral treatment of HIV-1 [ID3731]

Remdesivir for treating COVID-19 [ID3808]

Pembrolizumab with docetaxel for treating hormone-relapsed metastatic prostate cancer untreated with chemotherapy [ID3801]

Eryaspase with chemotherapy for previously treated advanced or metastatic pancreatic cancer [ID3781]

Naxitamab with GM-CSF for treating relapsed or refractory high-risk neuroblastoma [ID3769]

Eflornithine with sulindac for treating familial adenomatous polyposis [ID1543]